Table 2

Univariate analysis for aGVHD and cGVHD

aGVHD (90 d)PcGVHD (12 mo)P
Age     
 <10 15 (8-23) .249 11 (3-19) .001 
 ≥10 13 (1-25)  42 (23-61)  
Calendar period     
 1990-2000 13 (0-30)  30 (2-58)  
 2001-2007 22 (10-33) .952 23 (10-36) .393 
 2008-2012 21 (11-32)  15 (4-26)  
Donor type     
 HLA-matched related 9 (1.5-16) .026* 24 (11-37) .68 
 HLA-matched unrelated 31 (18-43)  20 (8-33)  
 HLA mismatch 31 (6-56)  0†  
Source of cells     
 BM 17 (8-26)  19 (8-30)  
 CB 27 (9-46) .247 0 (0-0) .006 
 PB 24 (7-40)  35 (16-55)  
Conditioning regimen     
 RIC 33 (10-57) .892 23 (0-46) .290 
 Myeloablative 19 (12-27)  19 (10-28)  
GVHD prophylaxis     
 CSA + MTX 11 (2-20) .006 23 (9-37) .540 
 No/only CSA 31 (19-42)  18 (7-29)  
In vivo T-cell depletion (ATG)     
 No 15 (5-25) .477 24 (10-38) .239 
 Yes 25 (15-35)  17 (7-28)  
MDS/AL     
 No MDS/
leukemia 		18 (9-27) .486 12 (4-21) .786 
 MDS/leukemia 36 (8-65)  22 (0-49)  
aGVHD (90 d)PcGVHD (12 mo)P
Age     
 <10 15 (8-23) .249 11 (3-19) .001 
 ≥10 13 (1-25)  42 (23-61)  
Calendar period     
 1990-2000 13 (0-30)  30 (2-58)  
 2001-2007 22 (10-33) .952 23 (10-36) .393 
 2008-2012 21 (11-32)  15 (4-26)  
Donor type     
 HLA-matched related 9 (1.5-16) .026* 24 (11-37) .68 
 HLA-matched unrelated 31 (18-43)  20 (8-33)  
 HLA mismatch 31 (6-56)  0†  
Source of cells     
 BM 17 (8-26)  19 (8-30)  
 CB 27 (9-46) .247 0 (0-0) .006 
 PB 24 (7-40)  35 (16-55)  
Conditioning regimen     
 RIC 33 (10-57) .892 23 (0-46) .290 
 Myeloablative 19 (12-27)  19 (10-28)  
GVHD prophylaxis     
 CSA + MTX 11 (2-20) .006 23 (9-37) .540 
 No/only CSA 31 (19-42)  18 (7-29)  
In vivo T-cell depletion (ATG)     
 No 15 (5-25) .477 24 (10-38) .239 
 Yes 25 (15-35)  17 (7-28)  
MDS/AL     
 No MDS/
leukemia 		18 (9-27) .486 12 (4-21) .786 
 MDS/leukemia 36 (8-65)  22 (0-49)  

MTX, methotrexate.

*

In pairwise comparison test of HLA-matched related vs unrelated, P = .006. Other pairwise comparisons for this variable were not significant (P > .4).

†

In the group of mismatched patients, there were only 7 evaluable subjects, and cGVHD occurred only in 1 patient at 18 mo.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal